EP4504165A1 — Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer
Assigned to Istituto Nazionale Tumori Irccs Fondazione G Pascale · Expires 2025-02-12 · 1y expired
What this patent protects
The present invention relates to a combination of an HDAC inhibitor and statins for use in the treatment of pancreatic cancer. Preferably the invention relates to a combination of valproic acid (VPA) or any of its salts and simvastatin (SIM). The combination of the invention syne…
USPTO Abstract
The present invention relates to a combination of an HDAC inhibitor and statins for use in the treatment of pancreatic cancer. Preferably the invention relates to a combination of valproic acid (VPA) or any of its salts and simvastatin (SIM). The combination of the invention synergistically improves the anti-proliferative and pro-apoptotic effect of conventional chemotherapy, as gemcitabine/taxol.
Drugs covered by this patent
- Beleodaq (belinostat) · Acrotech Biopharma
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.